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Abstract	
Background	Alcohol	use	disorders	(AUDs)	are	highly	prevalent	in	Europe,	but	only	a	minority	of	those	
affected	receive	treatment.		It	is	therefore	important	to	identify	factors	that	predict	treatment	in	order	
to	reframe	strategies	aimed	at	improving	treatment	rates.	
Methods	Representative	cross-sectional	study	with	patients	aged	18-64	from	primary	health	care	(PC,	
six	European	countries,	N=8,476,	data	collection	01/13	–	01/14)	and	from	specialized	health	care	(SC,	
eight	European	countries,	N=1,762,	data	collection	01/13	–	03/14).		For	descriptive	purposes	six	groups	
were	distinguished,	based	on	type	of	DSM-IV	AUD	and	treatment	setting.		Treatment	status	(yes/no)	for	
any	treatment	(model	1),	and	for	SC	treatment	(model	2)	were	main	outcome	measures	in	logistic	
regression	models.	
Results	AUDs	were	prevalent	in	PC	(12-month	prevalence:	11.8%;	95%	confidence	interval	(CI):11.2-
12.5%),	with	17.6%	receiving	current	treatment	(95%	CI:	15.3-19.9%).		There	were	clear	differences	
between	the	six	groups	regarding	key	variables	from	all	five	predictor	domains.	
Prediction	of	any	treatment	(model	1)	or	SC	treatment	(model	2)	was	successful	with	high	overall	
accuracy	(both	models:	95%),	sufficient	sensitivity	(model	1:	79%/	model	2:	76%)	and	high	specificity	
(both	models:	98%).		The	most	predictive	single	variables	were	daily	drinking	level,	anxiety,	severity	of	
mental	distress,	and	number	of	inpatient	nights	during	the	last	6	months.	
Conclusions	Variables	from	four	domains	were	highly	predictive	in	identifying	treatment	for	AUD,	with	
SC	treatment	groups	showing	very	high	levels	of	social	disintegration,	drinking,	comorbidity	and	
functional	losses.		Earlier	intervention	and	formal	treatment	for	AUD	in	PC	should	be	implemented	to	
reduce	these	high	levels	of	adverse	outcomes.	
Key	words	Alcohol	use	disorder,	Alcohol	dependence,	Treatment,	Specialized	care,	Primary	care,	Europe		
Word	count:	3,427	
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1. Introduction	
Treatment	of	alcohol	use	disorders	(AUDs)	is	one	of	the	biggest	challenges	for	mental	health.		On	the	
one	hand,	AUDs	are	among	the	most	prevalent	mental	disorders	in	the	European	Union	(EU)	with	an	
estimated	23	million	people	affected	in	2010	[1,	2],	with	high	associated	disability	[3,	4]	and	
standardized	mortality	ratios	(SMR;	a	ratio	quantifying	the	increase	or	decrease	in	mortality	of	a	specific	
group	–	people	with	AUD	in	treatment	–	compared	to	the	general	population	of	same	sex	and	age	[5])	
around	10	for	young	adults	[6].		Overall,	AUDs	have	the	second	highest	burden	of	disease	of	all	mental	
disorders	after	depression,	the	highest	in	men	[1].		On	the	other	hand,	treatment	rates	have	been	low	–	
in	fact	the	lowest	of	all	major	mental	disorders	[7]	–	with	about	10%	in	Europe	during	the	past	decade	
[8-10].	
Different	explanations	for	the	low	treatment	rate	for	AUDs	have	been	brought	forward.		Based	on	a	
large-scale	study	by	the	World	Health	Organization,	Üstün	and	Sartorius	[11]	claimed	that	primary	care	
physicians	(GPs)	do	not	recognize	mental	disorders,	and	therefore	neither	treat	nor	refer	them	to	
specialized	health	care	(SC).		Stigmatization	of	AUDs	may	be	another	reason	for	the	low	treatment	rate,	
as	it	was	found	to	be	higher	than	stigmatization	for	other	mental	disorders	in	general	population	studies	
[12],	and	may	be	a	barrier	for	people	affected	to	enter	treatment	[13-15].		A	third	main	reason	concerns	
the	perceived	need	of	medical	treatment	by	affected	people,	who	may	prefer	to	deal	with	the	problem	
by	themselves	[16,	17],	and	may	only	seek	help	if	they	“hit	bottom”	[18,	19].		Even	EU	treatment	
systems	with	their	reliance	on	SC	predominently	for	severely	affected	people	[20]	seem	to	reflect	similar	
thinking.		In	this	sense,	the	low	treatment	rate	could	be	explained	as	a	continuum	of	severity	of	AUDs,	
where	only	the	most	problematic	forms	(i.e.,	severe	alcohol	dependence	(AD)	according	to	ICD-10	[21]	
or	DSM-IV	[22],	or	AUDs	above	a	certain	criteria	threshold	in	DSM	5	[23])	are	seen	in	need	of	formal	
treatment,	whereas	the	less	severe	forms	would	take	care	of	themselves	by	natural	recovery/auto-
remission	[24,	25].		Severity	could	be	in	part	characterized	by	comorbidity	(both	somatic	and	mental;	
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[26-30]),	functionality	losses	(for	the	impact	of	functionality	limitations	on	treatment	seeking	see	[30-
32]),	or	social	disintegration	[19,	28].	
Two	recent	large-scale	representative	epidemiological	samples	in	primary	and	specialized	health	care	in	
six	and	eight	EU	countries,	respectively,	offered	a	unique	opportunity	to	further	investigate	AUDs	and	
treatment	pathways,	for	the	primary	health	care	sample	and	for	the	specialized	health	care	sample).		
First,	it	was	established	that	GPs	could	identify	AD	and	AUD	with	the	exception	of	younger	cases	[33],	
thus	not	corroborating	the	first	explanation	above.		Second,	we	wanted	to	examine	the	role	of	social	
disintegration,	drinking	behaviour,	co-morbidities	and	functionality	in	receiving	treatment.		The	main	
hypothesis	tested	predictability	of	any	or	SC	treatment	with	indicators	from	these	predictor	classes.		
	
	
2. Methods		
2.1. Sampling	procedures	
Both	study	samples	were	cross-sectional:	first,	we	sampled	8,476	primary	health	care	(PC)	patients	from	
358	GPs	across	six	European	countries	(patient	response	rate:	82.2%;	GP	response	rate:	43.6%)	between	
January	2013	and	January	2014	(see	also	[34,	35].		Representativeness	was	achieved	regionally	in	
countries	with	more	than	40	million	inhabitants	(Germany:	Saxony	and	Berlin,	Italy:	Friuli-Venezia	Giulia	
and	Tuscany,	Poland:	Łódź	and	Podkarpackie	provinces,	Spain:	Catalonia),	and	nationally	in	smaller	
countries	(Hungary,	Latvia).		Second,	1,767	patients	from	various	SC	settings	were	sampled	across	eight	
European	countries	between	January	2013	and	March	2014	(patient	response	rate:	82.73%;	institutional	
response	rate:	62.5%;	see	Web	Table	1	for	an	overview;	see	[36]	for	details).		Patients	receiving	SC	for	
AUDs	were	recruited	from	the	same	regions	and	countries	of	the	PC	sample	with	the	exception	of	
Poland	(provinces:	Pomorskie,	Warmińsko-Mazurskie,	Dolnośląskie,	Podlaskie,	Podkarpackie,	
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Małopolskie);	Austria	(one	region	Carinthia)	and	France	(whole	country)	were	added.		Both	samples	
were	restricted	to	patients	aged	18-64.			
Selection	of	PC	patients	was	carried	out	randomly	on	one	day	or	consecutive	days.		GPs	filled	in	a	short	
questionnaire	about	all	patients	for	the	next	day	if	prior	appointment	was	made	or	on	the	same	day	if	
GP	visits	were	mostly	spontaneous.		For	the	patient	interview,	we	contacted	all	patients	in	Hungary	and	
Spain	and	drew	subsamples	of	those	being	assessed	by	their	GP	in	all	remaining	countries,	with	different	
probabilities	based	on	GP’s	answers	about	alcohol	consumption	and	problems	(undersampling	
abstainers,	oversampling	AUD	cases).		Most	SC	patients	were	also	selected	by	presence	on	a	given	day.		
In	Poland,	admission	to	the	SC	facility	in	a	given	time	period	comprised	study	participation.	
2.2. Instruments	
In	addition	to	socio-demographic	assessment	including	measures	of	social	disintegration	[37]	
(unemployment,	not	being	married,	low	socio-economic	status	(SES)),	we	assessed	somatic	
(hypertension,	liver	problems)	and	mental	comorbidity	(anxiety,	depression)	both	via	GP	(PC	sample	
only)	and	interview.		We	used	the	Composite	International	Diagnostic	Interview	[38]	to	establish	12-
month	diagnoses	of	AUDs	according	to	the	DSM-IV	[22]	and	DSM-5	[23];	and	to	assess	current	drinking	
levels.		Further,	the	Kessler	Psychological	Distress	Scale	(K10	[39])	determined	the	extent	of	experienced	
mental	distress,	and	the	World	Health	Organization	Disability	Assessment	Schedule	2.0	(WHODAS	2.0	
[40,	41])	assessed	the	degree	of	functionality	losses	in	different	life	domains.		Custom-made	items	were	
applied	to	gain	information	on	current	or	lifetime	treatments;	and	on	somatic	and	mental	co-morbidities	
of	SC	patients.		All	patient	interviews	were	conducted	after	written	consent	was	given.		Compensation	
for	being	interviewed	was	offered	in	some	countries.	
Independently	from	and	in	addition	to	the	patient	interview,	all	PC	patients	were	assessed	by	their	
treating	GPs	using	a	brief	form.		The	form	comprised	questions	on	socio-demographics,	general	health	
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and	assessed	past	and	current	alcohol	use	and	alcohol-related	problems	and	possible	treatment	of	the	
patient	as	perceived	by	the	GP.	
One	of	the	main	outcome	variable	in	this	study	–	treatment	access	by	PC	patients	–	was	derived	by	a	
combination	of	GP	assessment	and	patient	interview.		GPs	provided	very	basic	treatment	information	
(distinguishing	only	between	psychosocial	and/or	pharmacological	AD	interventions),	whereas	the	
patients	themselves	disclosed	more	details	about	the	type	of	treatment	received	(e.g.	counselling,	
pharmacotherapy)	and	the	kind	of	health	professional	involved	(e.g.	GP,	psychotherapist,	psychiatrist).		
Our	definition	of	professional	treatment	included	group	therapies	led	by	health	professionals,	but	
excluded	mere	social	support	(e.g.	from	family,	friends)	or	interventions	from	non-health	professionals	
such	as	herbalists	and	priests.	
Patients	from	the	SC	sample	received	a	variety	of	interventions	–	depending	on	the	type	of	setting	they	
were	recruited	from.		Most	patients	were	treated	in	inpatient	clinics	(53.6%),	followed	by	outpatient	
centers	(32.8%).		The	remaining	patients	received	interventions	by	GPs,	psychiatrists	or	were	in	self-help	
groups.		Large	country-specific	differences	regarding	treatment	settings	were	prevalent,	for	more	
details,	see	Rehm	et	al.,	2015[36].	
For	descriptive	purposes,	the	following	six	exclusive	subgroups	were	created:	PC	patients	without	AUD;	
alcohol	abuse	(AA;	without	concurrent	AD)	in	PC	without	treatment;	AD	in	PC	without	treatment;	AUD	in	
PC	with	treatment	(mainly	for	AD);	AUD	in	SC	with	at	most	3	DSM-5	criteria;	and	AUD	in	SC	with	at	least	
4	DSM-5	criteria.		All	AUD	diagnoses	(AD,	AA)	were	determined	by	GP	and/or	CIDI	in	the	PC	sample,	
while	the	SC	patients’	were	diagnosed	with	CIDI	only.	
We	have	excluded	current	abstainers	or	very	light	drinkers	from	the	five	groups	with	AUD	in	analyses	
concerning	alcohol	measures,	as	they	did	not	reflect	the	original	drinking	level	associated	with	AUDs.	In	
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total,	336	women	(39.9%)	and	461	men	(22.7%)	were	excluded	due	to	less	than	10g	daily	alcohol	use	or	
missing	values	in	this	variable.	
2.3. Statistical	Analysis	
Descriptive	analyses	on	means,	proportions	and	their	uncertainty	were	carried	out	for	Tables	1,	2	and	3	
and	for	Web	Tables	2	and	3.		For	linear	trends	reported,	we	carried	out	sex-specific	linear	and	logistic	
regressions,	for	continuous	and	dichotomous	outcomes	respectively,	including	age	and	country	as	
further	predictors.		Linear	trends	were	carried	out	as	we	hypothesized	increasing	levels	of	problems	with	
increasing	severity	of	AUDs.	
Two	different	models	(1a	and	2a)	to	predict	treatment	included	sociodemographic	variables	(age,	sex,	
country);	indicators	for	social	disintegration	(unemployment,	marriage/cohabitating	status,	low	SES),	
somatic	comorbidity	(liver	problems),	mental	comorbidities	(depression,	anxiety,	mental	distress),	
functionality	losses	(disability	days,	inpatient	nights)	and	alcohol	consumption	patterns	(daily	ethanol	
intake)	as	independent	variables	in	logistic	regressions.		The	first	model	predicted	any	treatment,	i.e.	all	
cases	in	AUD	treatment	(one	PC	group	and	both	SC	groups)	vs.	untreated	cases	and	patients	without	
AUD,	while	the	second	model	predicted	SC	treatment	only	(see	Web	Table	4	and	5).		Both	models	
excluded	current	abstainers	and	very	light	drinkers	but	included	also	cases	from	countries	where	only	SC	
samples	were	assessed	(Austria	and	France).		Subsequently,	the	strongest	predictor	of	each	domain	
(social	disintegration,	mental	and	somatic	comorbidity,	functionality	loss,	and	alcohol)	was	determined	
in	each	model	(via	largest	effect	size)	and	entered	into	two	additional	models,	predicting	the	same	
outcome	(1b:	any	treatment;	2b:	specialized	treatment).		In	order	to	test	for	heterogeneity	on	the	
identified	predictors	between	the	included	countries,	we	ran	the	same	logits	for	each	country	separately	
and	entered	the	log	odds	of	each	independent	variable	of	the	five	domains	into	respective	meta	
analyses.		The	resulting	forest	plots	are	included	in	the	Web	Appendix	(Web	Figures	1-10)	and	report	I²	
as	the	measure	of	heterogeneity	[42].		The	same	procedure	was	repeated	separately	by	sex.			
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All	analyses	took	sampling	design	into	consideration	and	were	conducted	with	STATA	12.0	[43].		More	
detailed	information	on	sampling	techniques	and	other	methodological	aspects	are	published	elsewhere	
[33,	35].		Ethical	approval	was	obtained	in	all	countries.	
3. Results	
3.1. Prevalence	of	AUD	and	proportion	receiving	treatment	
Prevalence	of	AUD	was	high	(overall	12-month	prevalence:	11.8%,	95%	confidence	interval	(CI):	11.2-
12.5%;	men	19.9%,	95%	CI:	18.6-21.2%;	women	6.5%,	95%	CI:	5.8-7.1%;	for	details	see	Table	1),	with	AD	
being	the	more	prevalent	disease.		Current	treatment	rates	were	low	(overall	17.6%,	95%	CI:	15.3-
19.9%;	men	19.1%,	95%	CI:	16.2-22.1%;	women	14.5%,	95%	CI:	10.7-18.2%),	with	even	lower	rates	for	
lifetime	treatment	before	the	current	episode	indicating	that	for	many	patients	this	was	the	first	
treatment	episode.	
- Insert	Table	1	about	here	-		
3.2. Socio-demographic	indicators	
Web	Table	2a	and	2b	give	the	most	important	socio-demographic	indicators	for	women	and	men,	
respectively.		Social	disintegration	was	related	to	the	diagnostic	and	treatment	status:	the	indicators	of	
marriage,	unemployment,	and	SES	below	average	show	clear	trends	that	differentiate	people	between	
the	six	groups	with	SC	showing	the	highest	rate	of	disintegration.		For	age,	no	clear	trend	emerged,	but	
AUD	cases	in	treatment	were	older	(46.5	years,	standard	deviation	(SD):	10.2	years)	than	their	
counterparts	not	in	treatment	(42.8	years,	SD:	14.6	years;	Scheffé	test:	t=6.94,	p<.001)	
3.3. Alcohol	consumption	and	related	measures	
In	Table	2,	alcohol	consumption	measures	are	presented	across	all	subgroups.		Linear	trends	were	
observable	for	all	measures,	i.e.	with	SC	treatment	samples	showing	the	highest	level	of	drinking,	
followed	by	patients	in	PC	in	AUD	treatment,	untreated	AD	cases,	untreated	AA	cases,	and	PC	patients	
without	AUD	showing	the	lowest	level	of	drinking.		To	give	one	example	about	the	spread:	chronic	heavy	
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drinking	patterns	(at	least	100g	alcohol	daily)	were	present	in	more	than	every	second	SC	patient	with	at	
least	four	DSM-5	AUD	criteria	(57.6%,	95%	CI:	54.6-60.6%;),	compared	to	0.3%	(95%	CI:	0.2-0.5%)	in	the	
general	population	without	AUD.		The	former	group	consistently	showed	the	highest	values	in	all	alcohol	
measures.	
- Insert	Table	2	about	here	-		
3.4. Somatic	and	mental	comorbidity	
For	both	somatic	and	mental	comorbidity	we	see	a	gradient	for	the	groups	examined.		For	somatic	
comorbidity,	this	is	true	for	hypertension	and	liver	problems,	but	with	some	unexpected	results	for	SC	
(Table	3).		In	interpreting	these	results,	the	different	sources	should	be	taken	into	consideration:	SC	
results	were	self-reports,	whereas	the	results	for	PC	were	based	on	GP	judgement.			
For	mental	comorbidity,	i.e.,	depression,	anxiety	and	severe	mental	distress,	as	measured	with	K10	(see	
Table	3),	the	gradient	was	significant	but	less	pronounced	compared	to	drinking	indicators.		As	an	
example,	take	the	K10	summary	measure:	the	respective	proportions	with	marked	mental	distress,	as	
defined	by	reaching	the	threshold	of	21	points	on	a	scale	ranging	0-40	(for	the	threshold:	[44]),	rose	
from	5.2%	(95%	CI:	4.7-5.7%)	among	the	PC	patients	without	AUD	to	42.4%	(95%	CI:	39.6-45.2%)	among	
the	most	severe	patients	receiving	SC.	
- Insert	Table	3	about	here	-		
3.5. Functionality	losses	
The	degree	of	functionality	losses,	as	measured	by	the	extent	of	disability	in	various	life	domains,	also	
increased	along	the	groups	defined	(see	Web	Table	3	and	Figure	1).		On	average,	PC	patients	(general	
population)	could	not	carry	out	usual	activities	on	1.3	days	(SD:	4.6	days)	within	the	past	month	due	to	
any	health	condition,	compared	to	the	most	severely	affected	SC	patients	with	4.9	days	(SD:	8.1	days)	in	
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the	same	time	period;	the	other	groups	were	in	between.		Similar	differences	between	groups	were	
reported	for	number	of	inpatient	nights	during	the	past	six	months.	
- Insert	Figure	1	about	here	-		
3.6. Identification	and	treatment	seeking	
Overall,	the	six	groups	almost	looked	like	distinct	samples,	which	could	be	separated	based	on	the	
covariates	presented.		Specifically,	treatment	status	(any	vs.	no	treatment)	was	correctly	predicted	of	
95.5%	of	the	cases,	with	a	sensitivity	of	70.0%	and	a	specificity	of	98.4%	(positive	predictive	value:	
89.6%;	for	terminology	see	[45],	see	Model	1a,	Web	Table	4).		Inserting	the	regression	weights	for	
members	of	the	other	groups	did	result	in	the	following	proportions:	primary	care	patients	without	
AUD:	0.6%;	AA	without	treatment:	5.4%,	AD	without	treatment:	20.4%;	AUD	in	treatment	(PC	sample):	
54.4%;	SC	sample	with	at	most	3	AUD	criteria:	70.3%;	SC	sample	with	at	least	4	AUD	criteria:	86.5%	(see	
Web	Table	4).		In	other	words,	only	121	additional	people	of	all	the	persons	not	in	treatment	
(representing	1.6%	of	the	sample	N=7,614)	would	have	qualified	for	treatment	based	on	this	statistical	
prediction	model.			
The	indicators	described	above	could	similarly	predict	SC	treatment	vs.	all	other	groups	in	95.3%	of	the	
cases,	with	a	sensitivity	of	76.5%,	a	specificity	of	98.2%,	and	a	positive	predictive	value	of	87.1%	(see	
Model	2a,	Web	Table	4).		Moreover,	in	the	full	PC	sample	excluding	non-abstinent	patients	from	the	
AUD	groups,	only	137	out	of	7,730	would	have	qualified	for	SC	based	on	the	predictors	chosen	(1.8%)	
and	most	of	these	(N=76,	55.5%)	were	identified	by	the	GP	as	AD.		
Strongest	predictors	(see	Web	Table	5)	in	both	models	were	mean	daily	ethanol	intake,	anxiety,	severe	
mental	distress	as	measured	by	K10,	number	of	inpatient	nights	and	sex.		We	did	additional	models	with	
one	predictor	for	each	of	the	theoretically	hypothesized	predictor	classes	(social	disintegration,	drinking	
patterns,	somatic	comorbidity,	mental	comorbidity,	functionality	losses)	and	could	predict	almost	the	
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same	proportion	with	treatment	status	correctly	with	a	much	simpler	model	(see	Models	1b	and	2b,	
Web	Table	4	and	5).	
For	the	country-specific	models	(Web	Figures	1-30),	we	found	that	the	effect	sizes	of	indicators	of	social	
disintegration	(model	1b:	unemployment,	model	2b:	unmarried),	somatic	comorbidity	and	inpatient	
nights	(only	in	model	1b)	were	homogeneous	across	the	different	countries.		For	the	remaining	
indicators,	a	more	heterogeneous	picture	between	countries	was	found.		The	indicator	of	mental	
comorbidity	(anxiety)	was	identified	as	significant	predictor	in	four	out	of	five	countries,	with	varying	
effect	sizes	(ORs	ranging	from	4.09	to	21.44),	but	not	so	in	Germany.		For	drinking	patterns,	statistical	
heterogeneity	was	found	for	both	models	but	all	indicators	were	significant	across	all	observed	
countries	with	ORs	ranging	between	1.03	and	1.09.			
The	distribution	of	heterogeneity	across	the	different	indicators	and	countries	was	similar	when	
separated	by	sex.		The	most	striking	exception	to	this	observation	was	identified	in	Hungarian	females	
where	being	married	had	a	contrary	effect	compared	to	patients	of	the	same	sex	from	other	countries	
(OR=0.34,	95%	CI:	0.13-0.93).		Further,	we	observed	that	heterogeneity	was	more	prevalent	in	females	
than	in	males,	for	instance	in	liver	problems	(only	among	females	in	model	1b)	and	inpatient	nights	only	
among	females	in	both	models).		In	total,	the	results	can	be	seen	as	showing	high	homogeneity,	even	
though	for	some	indicators	the	effect	sizes	varied.	
	
4. Discussion	
AUDs	were	highly	prevalent,	but	only	a	small	proportion	received	current	treatment.		We	were	able	to	
show	a	marked	gradient	for	all	the	covariates	examined	for	patients	with	different	severity	of	AUD,	with	
SC	patients	showing	the	highest	level	of	problems.		Given	this	situation,	it	was	not	surprising	that	
treatment	status	could	be	predicted	with	high	sensitivity	and	specificity,	and	relatively	homogeneous	
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across	countries.		Before	we	discuss	the	implications	of	our	research,	we	would	like	to	discuss	
limitations.	
4.1. Limitations	
While	both	samples	were	based	on	representative	register-based	sampling,	more	than	55%	of	all	GPs	
and	37.5[1]%	SC	settings	selected	refused	participation.		This	is	not	surprising	given	the	busy	schedule	of	
PC	physicians	and	SC	facilities,	but	we	cannot	exclude	that	selected	facilities	not	participating	had	
different	characteristics	(for	general	considerations	of	selection	bias	see	[46]).		In	light	of	other	GP	
studies	with	probabilistic	sampling	techniques	from	regional	rosters	involving	personal	assessments,	our	
response	rate	can,	however,	be	considered	satisfactorily	[47,	48].		This	is	even	more	so	for	the	response	
rate	of	SC	facilities	selected.		The	individual	level	response	rate	(i.e.,	response	rate	for	patients	selected)	
was	higher	than	in	current	European	surveys	[49]	or	in	other	patients’	surveys	[50].	
Many	of	our	findings	are	based	on	self-report	and	interviews,	and	the	potential	bias	resulting,	while	
being	found	relatively	low	for	the	standardized	instruments	used	([41,	51-54]),	can	never	be	excluded.		
However,	for	hypertension	and	somatic	comorbidity	in	general,	self-reports	may	be	underestimating	the	
true	prevalence	(e.g.,	for	hypertension	see	[55]),	which	could	explain	the	relative	low	prevalence	in	SC.		
The	biggest	limitation	of	this	study	is	the	cross-sectional	nature,	which	does	not	allow	conclusions	about	
causality	[56].		Clearly,	longitudinal	designs	should	be	used	to	corroborate	key	results	and	conclusions	of	
this	study.	
Finally,	the	differences	between	SC	and	treatment	at	PC	levels	may	be	underestimated,	as	some	people	
who	were	identified	in	PC	levels	may	have	actually	had	their	reported	treatment	in	SC.	
4.2. .Discussion	of	key	results	
AUDs	were	quite	prevalent	in	PC,	above	twice	as	high	compared	to	general	population	surveys	[1,	2,	57].		
We	confirmed	that	only	a	minority	of	people	with	AUD	received	treatment,	even	though	our	numbers	
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were	higher	than	the	numbers	previously	reported	in	the	literature	[8,	10].		The	higher	treatment	rate	in	
our	study	may	be	due	to	two	reasons:	contrary	to	other	studies,	we	assessed	treatment	status	both	via	
GP	and	via	patient,	whereas	other	studies	were	based	on	one	measurement,	only.		In	particular,	it	may	
be,	that	the	GPs	included	interventions	defined	based	on	simple	questions	or	advice	about	the	drinking	
and	control	as	“treatment”	(see	[58],	for	the	situation	in	Germany).		Secondly,	we	had	a	very	wide	
definition	of	treatment,	including	interventions	of	all	health	care	professionals.		Thus,	before	concluding,	
that	the	treatment	rate	for	AUD	improved,	more	detailed	studies	are	necessary.	
We	could	further	confirm	that	receiving	treatment	was	highly	predicted	by	variables	from	four	
categories:	social	disintegration,	alcohol	consumption	levels,	somatic	and	mental	co-morbidities,	and	
functionality,	which	correctly	classified	almost	96%	of	all	participants’	overall	treatment	status;	
furthermore,	79%	in	treatment	and	76%	of	people	in	SC	were	correctly	predicted.		In	other	words,	
people	with	very	severe	AUD	were	referred	to	treatment	in	general,	and	to	SC	treatment	in	particular,	
based	on	these	four	classes	of	predictors.		But	are	the	algorithms	underlying	these	referrals	by	GPs,	or	
by	the	patients	themselves,	the	best	possible	for	the	treatment	system?		The	best	predictive	power	
could	be	found	for	average	alcohol	consumption	and	anxiety;	these	indicators	had	a	very	high	level	in	SC	
patients	with	an	average	daily	drinking	level	of	141.1g	(95%	CI:	135.1-147.0g)	and	a	prevalence	of	
anxiety	of	50.3%	(95%	CI:	47.8-52.9%).		It	may	be	questioned	if	these	values	do	not	indicate	that	
treatment	in	general	and	SC	treatment	in	particular	started	too	late.		The	same	question	arises	when	the	
very	high	proportions	of	liver	problems,	depression	or	losses	in	functionality	are	considered.			
Even	though	moralistic	approaches	to	AD	tend	to	consider	that	patients	need	to	“hit	bottom”	before	
they	can	start	a	recovery	process,	early	detection	of	alcohol	use/problems	has	been	shown	as	an	
important	step	towards	prevention	of	somatic	and	psychiatric	consequences	of	chronic	alcohol	
consumption.		Early	treatment	is	essential	for	prevention	of	alcohol	liver	disease	including	liver	cirrhosis	
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as	well	as	for	effective	treatment	of	comorbid	affective	disorders	(for	example	see	[59,	60]).		However,	
the	data	seem	to	indicate	that	most	treatment	at	the	PC	and	SC	level	in	Europe	is	delivered	to	people	
with	a	high	level	of	existing	comorbidity.	
Consider	the	following:	of	all	people	in	AUD	treatment,	based	on	the	most	comprehensive	meta-analysis	
to	date,	the	SMR	is	3.38	(95%	CI:	2.98-3.84)	for	men	and	4.57	(95%	CI:	2.72-7.65)	for	women	[6].		From	a	
public	health	concern,	even	more	important	is	the	age	gradient	in	SMR	in	both	sexes,	in	men	ranging	
from	over	9-fold	for	the	under	30	year	olds	to	about	2-fold	for	the	over	60	year	olds,	and	in	women	
ranging	from	almost	14-fold	to	3-fold	in	the	same	age	groups.		Based	on	another	meta-analysis,	these	
mortality	risks	could	be	considerably	reduced,	if	volume	of	alcohol	consumption	were	reduced,	to	about	
35%	(95%	CI:	20-60%)	for	those	who	reached	abstention	and	to	61%	(95%	CI:	39-94%)	for	those	who	did	
not	reach	abstention	but	substantially	reduced	their	consumption	[61,	62].		In	other	words:	if	people	
with	AUD	would	receive	interventions	effective	in	reducing	alcohol	consumption,	a	substantial	
proportion	of	the	mortality	associated	with	AUD	could	be	reduced	[9].	
4.3. Conclusions	
AUDs	are	prevalent	and	are	associated	with	high	comorbidity	and	mortality.		The	data	indicate	that	
there	may	be	a	non-structured	stepped	care	approach	based	on	drinking	level	and	associated	harm.		
Hence	treatment	reaches	patients	after	a	lot	of	alcohol-attributable	harm	has	already	occurred.		To	
avoid	this	harm,	treatment	should	be	offered	much	sooner,	and	GPs	need	to	be	thoroughly	involved.		
They	have	an	outstanding	role	in	this	by	identifying	patients	at	an	early	stage	of	AD,	before	health	is	
more	seriously	compromised.		Many	early	stage	AD	(Spithoff	&	Kahan,	2015),	as	well	as	early	stage	
anxiety	(Culpepper,	2002),	depression	(Linde	et	al.,	2015)	or	hypertension	can	be	treated	at	the	PC	level	
(Alexander,	1998).		If	not	willing	to	treat	by	themselves,	GPs	should	refer	to	SC.		A	revision	of	the	existing	
epidemiological	models	should	also	be	proposed	to	include	PC-centered-analyses	in	national	datasets	in	
addition	to	the	current	practice	of	general	population	surveys	(Manthey	et	al.,	in	press	=	current	35).		
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Moreover,	the	link	between	social	disintegration	and	AUD	indicates	the	importance	of	determinants	of	
health	and	the	importance	of	an	integrated,	public	health-led,	systemic	approach	[63,	64].	
Can Fam Physician. 2015	Jun;61(6):515-521.	
Primary care management	of	alcohol	use	disorder	and	at-risk	drinking:	Part	2:	counsel,	prescribe,	connect.	
Spithoff S1, Kahan M2.	
	
J Clin Psychiatry. 2002;63	Suppl	8:35-42.	
Generalized	anxiety	disorder	in	primary	care:	emerging	issues	in	management	and	treatment.	
Culpepper L1.	
	
Ann Fam Med. 2015	Jan-Feb;13(1):56-68.	doi:	10.1370/afm.1719.	
Effectiveness	of	psychological	treatments	for depressive disorders	in primary care:	systematic	review	and	meta-analysis.	
Linde K1, Sigterman K2, Kriston L3, Rücker G4, Jamil S2, Meissner K5, Schneider A2.	
	
	 	
17	
	
	
	
	
Role	of	funding	source	
The	study	was	financially	supported	by	an	investigator	initiated	grant	(grant	number	414209)	to	the	first	
author	and	the	GWT-TUD	(Gesellschaft	für	Wissens-	und	Technologietransfer	der	TU	Dresden	mbH	–	
company	with	limited	liabilities	for	transferring	knowledge	and	technology	of	the	Dresden	University	of	
Technology,	Germany)	by	Lundbeck	(Copenhagen/Denmark).		The	study	sponsor	has	no	role	in	design	
and	conduct	of	the	study;	collection,	management,	analysis,	and	interpretation	of	the	data;	and	
preparation,	review,	or	approval	of	the	manuscript.		The	corresponding	author	hereby	states	that	no	
author	has	been	reimbursed	for	writing	this	manuscript.	
Contributors	
JR,	AG	and	MW	conceptualized	the	APC	study	and	served	as	PI.		All	authors	except	JM	and	JR	served	as	
site	PIs	and	organized	and	supervised	fieldwork,	and	helped	in	data	cleaning.		JM	and	JR	conceptualized	
the	data	analyses,	helped	in	data	cleaning	and	quality	control,	and	conducted	the	quantitative	data	
analyses.		JR	wrote	JR	wrote	a	first	draft	of	the	paper,	and	all	authors	contributed	to	and	approved	of	
the	final	version.	
Conflict	of	interest	statement	(alphabetical	order	of	abbreviated	names):		
AG:	reports	grants	and	personal	fees	from	Lundbeck	and	D&A	Pharma	during	the	conduct	of	the	study	
and	grants	from	TEVA	and	personal	fees	from	Abbivie	outside	the	submitted	work.	
JM:	no	potential	conflict	of	interest	stated.		
JR:	reports	grants	from	GWT-TUD	during	the	conduct	of	the	study	and	grants,	personal	fees	and	being	
board	member	(Nalmefene)	for	Lundbeck	outside	the	submitted	work.		
MW:	reports	personal	fees	from	AOP	Orphan,	Berlin	Chemie,	Janssen,	Lundbeck,	D&A	Pharma,	Reckitt	
Benckiser,	and	Servier	outside	the	submitted	work.	
PS:	reports	grants	from	University	of	Dresden	during	the	conduct	of	the	study	and	being	primary	care	
board	member	for	Lundbeck	outside	the	submitted	work.	
			
	 	
18	
	
	
	
	
Reference	List	
	
[1]	Wittchen	HU,	Jacobi	F,	Rehm	J,	Gustavsson	A,	Svensson	M,	Jönsson	B,	et	al.	The	size	and	burden	of	
mental	disorders	and	other	disorders	of	the	brain	in	Europe	2010.	Eur	Neuropsychopharmacol.	
2011;21:655-79.	
[2]	Rehm	J,	Anderson	P,	Barry	J,	Dimitrov	P,	Elekes	Z,	Feijão	F,	et	al.	Prevalence	of	and	potential	
influencing	factors	for	alcohol	dependence	in	Europe.	Eur	Addict	Res.	2015;21:6-18.	
[3]	Samokhvalov	AV,	Popova	S,	Room	R,	Ramonas	M,	Rehm	J.	Disability	associated	with	alcohol	abuse	
and	dependence.	Alcohol	Clin	Exp	Res.	2010;34:1871-8.	
[4]	Rehm	J,	Dawson	D,	Frick	U,	Gmel	G,	Roerecke	M,	Shield	KD,	et	al.	Burden	of	disease	associated	with	
alcohol	use	disorders	in	the	United	States	Alcohol	Clin	Exp	Res.	2014;38:1068-77.	
[5]	Rothman	KJ,	Greenland	S,	Lash	TL.	Modern	Epidemiology,	3rd	ed.	Philadelphia,	PA:	Lippincott	
Williams	&	Wilkins;	2008.	
[6]	Roerecke	M,	Rehm	J.	Alcohol	use	disorders	and	mortality	-	A	systematic	review	and	meta-analysis.	
Addiction.	2013;108:1562-78.	
[7]	Kohn	R,	Saxena	S,	Levav	I,	Saraceno	B.	The	treatment	gap	in	mental	health	care.	Bull	World	Health	
Org.	2004;82:858-66.	
[8]	Alonso	J,	Angermeyer	MC,	Bernert	S,	Bruffaerts	R,	Brugha	TS,	ESEMeD/MHEDEA	Investigators.	Use	of	
mental	health	services	in	Europe:	results	from	the	European	Study	of	the	Epidemiology	of	Mental	
Disorders	(ESEMeD)	project.	Acta	Psychiat	Scand.	2004;109:47-54.	
[9]	Rehm	J,	Shield	KD,	Rehm	MX,	Gmel	G,	Frick	U.	Modelling	the	impact	of	alcohol	dependence	on	
mortality	burden	and	the	effect	of	available	treatment	interventions	in	the	European	Union.	Eur	
Neuropsychopharmacol.	2013;23:89-97.	
[10]	Rehm	J,	Shield	KD,	Rehm	MX,	Gmel	G,	Jr.,	Frick	U.	Alcohol	consumption,	alcohol	dependence,	and	
attributable	burden	of	disease	in	Europe:	potential	gains	from	effective	interventions	for	alcohol	
dependence.	Toronto,	Canada:	Centre	for	Addiction	and	Mental	Health;	2012.	
[11]	Üstün	BT,	Sartorius	N.	Mental	illness	in	general	health	care.	An	international	study.	West	Sussex,	
England:	John	Wiley	&	Sons	(published	on	behalf	of	World	Health	Organization);	1995.	
[12]	Schomerus	G,	Lucht	M,	Holzinger	A,	Matschinger	H,	Carta	MG,	Angermeyer	MC.	The	stigma	of	
alcohol	dependence	compared	with	other	mental	disorders:	a	review	of	population	studies.	Alcohol	
Alcohol.	2011;46:105-12.	
[13]	Keyes	KM,	Hatzenbuehler	ML,	McLaughlin	KA,	Link	B,	Olfson	M,	Grant	BF,	et	al.	Stigma	and	
treatment	for	alcohol	disorders	in	the	United	States.	Am	J	Epidemiol.	2010;172:1364-72.	
[14]	Mojtabai	R,	Chen	LY,	Kaufmann	CN,	Crum	RM.	Comparing	barriers	to	mental	health	treatment	and	
substance	use	disorder	treatment	among	individuals	with	comorbid	major	depression	and	substance	use	
disorders.	J	Subst	Abuse	Treat.	2014;46:268-73.	
[15]	Finn	SW,	Bakshi	AS,	Andréasson	S.	Alcohol	consumption,	dependence,	and	treatment	barriers:	
perceptions	among	nontreatment	seekers	with	alcohol	dependence.	Subst	Use	Misuse.	2014;49:762-9.	
[16]	Saunders	SM,	Zygowicz	KM,	D'Angelo	BR.	Person-related	and	treatment-related	barriers	to	alcohol	
treatment.	J	Subst	Abuse	Treat.	2006;30:261-70.	
[17]	Cohen	E,	Feinn	R,	Arias	A,	Kranzler	HR.	Alcohol	treatment	utilization:	findings	from	the	National	
Epidemiologic	Survey	on	Alcohol	and	Related	Conditions.	Drug	Alcohol	Depend.	2007;86:214-21.	
[18]	Nordström	G,	Berglund	M.	Successful	adjustment	in	alcoholism.	Relationships	between	causes	of	
improvement,	personality,	and	social	factors.	J	Nerv	Ment	Dis.	1986;174:664-8.	
[19]	Mäkelä	K,	Arminen	I,	Bloomfield	K,	Eisenbach-Stangl	I,	Bergmark	KH,	Kurube	N,	et	al.	Alcoholics	
Anonymous	as	a	mutual-help	movement:	A	study	in	eight	societies.	Madison,	WI:	University	of	
Wisconsin	Press;	1996.	
19	
	
	
	
	
[20]	Gossop	M.	The	treatment	mapping	survey:	A	descriptive	study	of	drug	and	alcohol	treatment	
responses	in	23	countries.	Drug	Alcohol	Depend.	1995;39:7-14.	
[21]	World	Health	Organization.	The	ICD-10	classification	of	mental	and	behavioural	disorders:	
Diagnostic	criteria	for	research.	Geneva:	World	Health	Organization;	1993.	
[22]	American	Psychiatric	Association.	Diagnostic	and	statistical	manual	of	mental	disorders	(4th	edition,	
text	revision).	Washington,	DC:	American	Psychiatric	Association;	2000.	
[23]	American	Psychiatric	Association.	Substance	Use	and	Addiction-Related	Disorders.		Diagnostic	and	
statistical	manual	of		mental	disorders	(5th	ed).	Arlington,	VA:	American	Psychiatric	Association,;	2013.	
p.	481-589.	
[24]	Sobell	LC,	Ellingstad	TP,	Sobell	MB.	Natural	recovery	from	alcohol	and	drug	problems:	
methodological	review	of	the	research	with	suggestions	for	future	directions.	Addiction.	2000;95:749-
64.	
[25]	Sobell	LC,	Sobell	MB,	Toneatto	T,	Leo	GI.	What	triggers	the	resolution	of	alcohol	problems	without	
treatment.	Alcohol	Clin	Exp	Res.	1993;17:217-24.	
[26]	Jané-Llopis	E,	Matytsina	I.	Mental	health	and	alcohol,	drugs	and	tobacco:	a	review	of	the	
comorbidity	between	mental	disorders	and	the	use	of	alcohol,	tobacco	and	illicit	drugs.	Drug	Alcohol	
Rev.	2006;25:515-36.	
[27]	Lahmek	P,	Berlin	I,	Michel	L,	Berghout	C,	Meunier	N,	Aubin	HJ.	Determinants	of	improvement	in	
quality	of	life	of	alcohol-dependent	patients	during	an	inpatient	withdrawal	programme.	Int	J	Med	Sci.	
2009;6:160-7.	
[28]	Dawson	DA,	Godstein	RB,	Grant	BF.	Factors	associated	with	first	utilization	of	different	types	of	care	
for	alcohol	problems.	J	Stud	Alcohol	Drugs.	2012;73:647-56.	
[29]	Proudfoot	H,	Teesson	M,	Australian	National	Survey	of	Mental	Health	Wellbeing.	Who	seeks	
treatment	for	alcohol	dependence?	Findings	from	the	Australian	national	survey	of	mental	health	and	
wellbeing.	Soc	Psychiatry	Psychiatr	Epidemiol.	2002;37:451-6.	
[30]	Hasin	DS,	Stinson	FS,	Grant	BF.	Prevalence,	correlates,	disability	and	comorbidity	of	DSM-IV	alcohol	
abuse	and	dependence	in	the	United	States:	results	from	the	National	Epidemiologic	Survey	on	Alcohol	
and	Related	Conditions.	Arch	Gen	Psychiatry.	2007;64:830-42.	
[31]	Üstün	T,	Chatterji	S,	Rehm	J.	Limitations	of	diagnostic	aradigm:	it	doesn't	explain	"need".	Arch	Gen	
Psychiatry.	1998;55:1145-6.	
[32]	Ormel	J,	VonKorff	M,	Üstün	TB,	Pini	S,	Korten	A,	Oldehinkel	T.	Common	mental	disorders	and	
disability	across	cultures.	Results	from	the	WHO	Collaborative	Study	on	Psychological	Problems	in	
General	Health	Care.	JAMA.	1994;272:1741-8.	
[33]	Rehm	J,	Allamani	A,	Elekes	Z,	Jakubczyk	A,	Landsmane	I,	Manthey	J,	et	al.	General	practitioners	
recognizing	alcohol	dependence:	a	large	cross-sectional	study	in	six	European	countries.	Ann	Fam	Med.	
2015;13:28-32.	
[34]	Rehm	J,	Allamani	A,	Elekes	Z,	Jakubczyk	A,	Manthey	J,	Probst	P,	et	al.	Alcohol	dependence	and	
treatment	utilization	in	Europe	-	a	representative	cross-sectional	study	in	primary	care.	BMC	family	
practice.	in	press.	
[35]	Manthey	J,	Gual	A,	Jakubczyk	A,	Pieper	L,	Probst	C,	Struzzo	P,	et	al.	Alcohol	use	disorders	in	Europe:	
A	comparison	of	general	population	and	primary	health	care	prevalence	rates.	Journal	of	Substance	Use.	
in	press.	
[36]	Rehm	J,	Allamani	A,	Aubin	HJ,	Elekes	Z,	Frick	U,	Jakubczyk	A,	et	al.	People	with	alcohol	use	disorders	
in	specialized	care	in	eight	different	European	countries.	Alcohol	Alcohol.	2015;50:310-8.	
[37]	Andrén	KG,	Rosenqvist	U.	An	ecological	study	of	the	relationship	between	risk	indicators	for	social	
disintegration	and	use	of	a	somatic	emergency	department.	Soc	Sci	Med.	1987;25:1121-7.	
20	
	
	
	
	
[38]	Kessler	RC,	Üstün	TB.	The	World	Mental	Health	(WMH)	Survey	Initiative	version	of	the	World	Health	
Organization	(WHO)	Composite	International	Diagnostic	Interview	(CIDI).	Int	J	Methods	Psychiatr	Res.	
2004;13:93-121.	
[39]	Kessler	RC,	Barker	PR,	Colpe	LJ,	Epstein	JF,	Gfroefer	JC,	Hiripi	E,	et	al.	Screening	for	serious	mental	
illness	in	the	general	population.	Arch	Gen	Psychiatry.	2003;60:184-9.	
[40]	Üstün	TB,	Chatterji	S,	Kostanjsek	N,	Rehm	J,	Kennedy	C,	Epping-Jordan	J,	et	al.	Developing	the	World	
Health	Organization	Disability	Assessment	Schedule	2.0.	Bull	World	Health	Org.	2010;88:815-23.	
[41]	Üstün	TB,	Kostanjsek	N,	Chatterji	S,	Rehm	J.	Measuring	Health	and	Disability.	Manual	for	WHO	
Disability	Assessment	Schedule	WHODAS	2.0.	Geneva,	Switzerland:	World	Health	Organization;	2010.	
[42]	Higgins	JP,	Thompson	SG.	Quantifying	heterogeneity	in	a	meta-analysis.	Statistics	in	medicine.	
2002;21:1539-58.	
[43]	Stata	Corporation.	Stata	Statistical	Software	(Version	12).	College	Station,	TX:	Stata	Corporation	LP;	
2011.	
[44]	Australian	Bureau	of	Statistics.	Use	of	the	Kessler	Psychological	Distress	Scale	in	ABS	Health	Surveys,	
Australia,	2007-08.	2012.	
[45]	Fleiss	JL,	Levin	B,	Cho	Paik	M.	Statistical	Methods	for	Rates	and	Proportions,	Third	Edition.	Hoboken,	
New	Jersey:	John	Wiley	&	Sons;	2003.	
[46]	Hernán	MA,	Hernández-Díaz	S,	Robins	JM.	A	structural	approach	to	selection	bias.	Epidemiology.	
2004;15:615-25.	
[47]	Wittchen	HU,	Glaesmer	H,	März	W,	Stalla	GK,	Lehnert	H,	Zeiher	AM,	et	al.	Cardiovascular	risk	
factors	in	primary	care:	methods	and	baseline	prevalence	rates	-	the	DETECT	program.	Curr	Med	Res	
Opin.	2005;21:619-29.	
[48]	Creavin	ST,	Creavin	AL,	Mallen	CD.	Do	GPs	respond	to	postal	questionnaire	surveys?	A	
comprehensive	review	of	primary	care	literature.	Family	practice.	2011;28:461-7.	
[49]	Baruch	Y.	Survey	response	rate	levels	and	trends	in	organizational	research.	Human	Relations.	
2008;61:1139-60.	
[50]	Garratt	AM,	Solheim	E,	Danielsen	K.	National	and	cross-national	surveys	of	patient	experiences:	a	
structured	review.	Rapport	nr	7-2008.	Oslo:	Nasjonalt	kunnskapssenter	for	helsetjenesten;	2008.	
[51]	Garin	O,	Ayuso-Mateos	JL,	Almansa	J,	Nieto	M,	Chatterji	S,	Vilagut	G,	et	al.	Validation	of	the	World	
Health	Organization	Disability	Assessment	Schedule,	WHODAS-2"	in	patients	with	chronic	diseases.	
Health	Qual	Life	Outcomes.	2010;8:51.	
[52]	Furukawa	TA,	Kessler	RC,	Slade	T,	Andrews	G.	The	performance	of	the	K6	and	K10	screening	scales	
for	psychological	distress	in	the	Australian	National	Survey	of	Mental	Health	and	Well-Being.	Psychol	
Med.	2003;33:357-62.	
[53]	Wittchen	HU.	Reliability	and	validity	studies	of	the	WHO-Composite	International	Diagnostic	
Interview	(CIDI):	A	critical	review.	J	Psychiatr	Res.	1994;28:57-84.	
[54]	Üstün	BT,	Compton	W,	Mager	D,	Babor	T,	Baiyewu	O,	Chatterji	S,	et	al.	WHO	study	on	the	reliability	
and	validity	of	the	alcohol	and	drug	use	disorder	instruments:	overview	of	methods	and	results.	Drug	
Alcohol	Depend.	1997;47:161-9.	
[55]	Neuhauser	H,	Thamm	M,	Ellert	U.	Blutdruck	in	Deutschland	2008-2011.	Ergebnisse	der	Studie	zur	
Gesundheit	Erwachsener	in	Deutschland	(DEGS1).	Bundesgesundheitsbl	2013;56:795-801.	
[56]	Shadish	WR,	Cook	TD,	Campbell	DT.	Experimental	and	Quasi-Experimental	Designs	for	Generalized	
Causal	Inference.	New	York,	U.S.:	Houghton	Mifflin	Company;	2002.	
[57]	Rehm	J,	Room	R,	Van	den	Brink	W,	Jacobi	F.	Alcohol	use	disorders	in	EU	countries	and	Norway:	an	
overview	of	the	epidemiology.	Eur	Neuropsychopharmacol.	2005;15:377-88.	
21	
	
	
	
	
[58]	Kraus	L,	Piontek	D,	Pfeiffer-Gerschel	T,	Rehm	J.	Inanspruchnahme	gesundheitlicher	Versorgung	
durch	Alkoholabhängige	[Health	care	utilization	of	people	with	alcohol	dependence].	Suchttherapie.	
2015;16:18-26.	
[59]	Farren	CK,	Snee	L,	Daly	P,	McElroy	S.	Prognostic	factors	of	2-year	outcomes	of	patients	with	
comorbid	bipolar	disorder	or	depression	with	alcohol	dependence:	importance	of	early	abstinence.	
Alcohol	Alcohol.	2013;48:93-8.	
[60]	Fagan	KJ,	Irvine	KM,	Kumar	S,	Bates	A,	Horsfall	LU,	Feeney	GF,	et	al.	Assessment	of	alcohol	histories	
obtained	from	patients	with	liver	disease:	opportunities	to	improve	early	intervention.	Intern	Med.	
2013;43:1096-102.	
[61]	Roerecke	M,	Gual	A,	Rehm	J.	Reduction	of	alcohol	consumption	and	subsequent	mortality	in	alcohol	
use	disorders:	systematic	review	and	meta-analysis.	J	Clin	Psychiatry.	2013;74:e1181-e9.	
[62]	Rehm	J,	Roerecke	M.	Reduction	of	drinking	in	problem	drinkers	and	all-cause	mortality.	Alcohol	
Alcohol.	2013;48:509-13.	
[63]	Colom	J,	Scafato	E,	Segura	L,	Gandin	C,	Struzzo	P.	Brief	Interventions	implementation	on	alcohol	
from	the	European	health	systems	perspective.	Front	Psychiatry.	2014;5:161.	
[64]	World	Health	Organization.	Strengthening	European	health	systems	as	a	continuation	of	the	WHO	
Regional	Office	for	Europe’s	Country	Strategy	“Matching	services	to	new	needs”.		Regional	Committee	
for	Europe:	Fifty-fifth	session.	Bucharest,	Romania2005.	
	
	 	
